Background Human papillomavirus (HPV) vaccination offers potential for primary prevention
of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical …

Background: Prophylactic human papilloma virus (HPV) vaccines represent a promising
option for cervical cancer (CC) prevention in countries where screening, diagnostics and …

Background: Human papillomavirus (HPV) epidemiology and screening practices vary
considerably between countries and specific analyses are required to estimate the impact of …

Background To eliminate cervical cancer as a public health problem, the World Health
Organization had recommended routine vaccination of adolescent girls with two doses of the …

Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now
licensed for use in Canada and many other countries. We sought to estimate the number …

Background Despite the high burden of cervical cancer, access to preventive measures
remains low in India. A single-dose immunisation schedule could facilitate the scale-up of …

We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The
Netherlands in addition to cervical cancer screening. For this purpose, we developed a …

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical
cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated …

Background Current prophylactic vaccines against human papillomavirus (HPV) target two
oncogenic types (16 and 18) that contribute to 70% of cervical cancer cases worldwide. Our …

Public health measures to prevent cervical cancer (CC) currently rely on early detection and
excision of precancerous lesions. The recent identification of oncogenic HPV infections as a …